Nevertheless, a remarkable intrinsic drug resistance of a large proportion of CRC cell lines to new-generation mTOR inhibitors, including both NVP-BEZ235 and pp242 compounds, was also described, warranting further studies [162]. The gene discussed is MTOR; the disease is colorectal carcinoma.